Bavarian Nordic secures a government contract for smallpox/mpox vaccine
Valued over DKK 700 million, deliveries start in 2026 with revenue recognized mainly in 2027.
See the latest news and media coverage for Bavarian Nordic. We track all announcements, press releases, and industry mentions in real time, all in one place.
Biopharmaceutical vaccine company
bavarian-nordic.comLast updated
In short: Bavarian Nordic reported strong 2025 revenue of DKK 6,244 million, secured major vaccine contracts, and initiated a CEO transition and board changes.
Valued over DKK 700 million, deliveries start in 2026 with revenue recognized mainly in 2027.
The vaccines will help protect vulnerable communities amid an active outbreak, supporting the public health response.
The company intends to repurchase shares for up to DKK 150 million by July 10, 2026, as part of its capital structure adjustment.
Revenue was DKK 1,058 million, EBITDA margin 16%, and full-year guidance upgraded.
COPENHAGEN, Denmark, June 15, 2026 - Bavarian Nordic A/S (OMX: BAVA) announces transactions under the share buy-back program launched on June 2, 2026, under which...
Nordea will again be part of the C25 index on Monday, June 22, instead of Bavarian Nordic, which is shown the door. »The announcement and the replacement...
Bavarian Nordic A/S (OMX: BAVA) today announced the award of a government contract valued over DKK 700 million to supply its ...
E-newspaper Front Page News Sports Editorial Crime Money Entertainment Consumption Page 9 Buy Ekstra Bladet+ Buy the newspaper 1224 - Tip Ekstra Bladet Services They enjoyed...
Track Bavarian Nordic and your other target companies to get real-time alerts and weekly summaries delivered straight to your inbox.
Browse news for competitors to Bavarian Nordic and other trending companies.